Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent st...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-05, Vol.22 (10), p.5383
Main Authors: Vathiotis, Ioannis A., Gomatou, Georgia, Stravopodis, Dimitrios J., Syrigos, Nikolaos
Format: Article
Language:English
Subjects:
Antigens
Antitumor activity
Apoptosis
Bone cancer
cancer
Cancer therapies
Cell death
Extracellular matrix
Immune checkpoint
Immune system
L1 protein
Ligands
Lung cancer
Lymphocytes
Lymphocytes T
Melanoma
Mesenchyme
Metastases
Metastasis
PD-1
PD-1 protein
PD-L1
PD-L1 protein
progression
Proteins
Review
Skin cancer
Transcription factors
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent studies have unveiled a distinct, tumor-intrinsic, potential role for PD-L1. In this review, we focus on tumor-intrinsic PD-L1 signaling and delve into preclinical evidence linking PD-L1 protein expression with features of epithelial-to-mesenchymal transition program, cancer stemness and known oncogenic pathways. We further summarize data from studies supporting the prognostic significance of PD-L1 in different tumor types. We show that PD-L1 may indeed have oncogenic potential and act as a regulator of tumor progression and metastasis.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22105383